Drug intelligence / Profile preview

EMP-015

Development stage: Preclinical
Lead developer: Empirico
Modality: Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

EMP-015 is an investigational small interfering RNA (siRNA) drug candidate developed by Empirico. It utilizes a GalNAc-conjugated siRNA modality, which enables targeted delivery to the liver. The primary therapeutic focus of EMP-015 is in cardiovascular and metabolic diseases. The specific molecular target and mechanism of action have not been publicly disclosed, but as a GalNAc-siRNA, it likely acts by silencing gene expression in hepatocytes relevant to cardiometabolic conditions[3].

Targets

ASGPR (Asialoglycoprotein Receptor 1)

Beyond the preview

Go deeper on EMP-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP-015.

Explore the full profile